Openbookopenbook
Equity
ANI Pharmaceuticals Inc(ANIP)
USD --+0.00%
Reward74High
Risk24Low
📊75%Data
Revenue growing 30% YoY
ANIP
+0.0 · +0.00%
USD · NASDAQ
ANI Pharmaceuticals Inc | Healthcare
Quality Compounder
Market Cap:1.77Bn
ℹ️
Reward Rating
74
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
24
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ANIP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $110.63.

What is ANI Pharmaceuticals Inc?

, a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

ANIP · Verdict

Strong reward · low risk

ANIP scores well on valuation and growth with no major weaknesses flagged in the model.

Based on 88% data coverage

ANIP · Verdict

What’s working & what to watch

Strengths 6

  • Valuation88/100

    P/E 8.9× · PEG 1.06

  • Growth87/100

    Revenue +40.8% CAGR

  • Cash flow81/100

    19% free-cash-flow margin

  • Volatility80/100

    Top decile vs peers

  • Balance sheet76/100

    Interest covered 5.8×

  • Profitability67/100

    9% net margin · 16% ROE

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is ANI Pharmaceuticals Inc?

, a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.77B, and a P/E ratio of 23.5x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (74)

The scoring profile indicates a strong reward potential, driven primarily by valuation and growth. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.77B
P/E Ratio23.4849
Dividend YieldN/A
52 Week High99.5
52 Week Low56.71
Last AnnualDecember
IPO Date5/5/2000
IncorporatedUSA
Shares Outstanding23M
No. of Employees970
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta0.435
CurrencyUSD
Websitewww.anipharmaceuticals.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.